ZYCLARA Drug Patent Profile

Which patents cover Zyclara, and when can generic versions of Zyclara launch?

Zyclara is a drug marketed by Bausch and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-nine patent family members in thirty-two countries.

The generic ingredient in ZYCLARA is imiquimod. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the imiquimod profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyclara

A generic version of ZYCLARA was approved as imiquimod by FOUGERA PHARMS on February 25^th, 2010.

Summary for ZYCLARA

International Patents:	59
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	123
Clinical Trials:	10
Drug Prices:	Drug price information for ZYCLARA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYCLARA
What excipients (inactive ingredients) are in ZYCLARA?	ZYCLARA excipients list
DailyMed Link:	ZYCLARA at DailyMed

See drug prices for ZYCLARA

See drug sales revenues for ZYCLARA

Recent Clinical Trials for ZYCLARA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aalborg University	N/A
National Cancer Institute (NCI)	Early Phase 1
Melissa Pugliano-Mauro	Phase 1

See all ZYCLARA clinical trials

Pharmacology for ZYCLARA

Mechanism of Action	Interferon Inducers
Physiological Effect	Increased Cytokine Activity Increased Cytokine Production

Paragraph IV (Patent) Challenges for ZYCLARA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYCLARA	Cream	imiquimod	2.5%	022483	1	2014-06-17
ZYCLARA	Cream	imiquimod	3.75%	022483	1	2012-08-08

US Patents and Regulatory Information for ZYCLARA

ZYCLARA is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ZYCLARA	imiquimod	CREAM;TOPICAL	022483-002	Jul 15, 2011		RX	Yes	Yes	8,222,270
Bausch	ZYCLARA	imiquimod	CREAM;TOPICAL	022483-001	Mar 25, 2010	AB	RX	Yes	Yes	8,598,196
Bausch	ZYCLARA	imiquimod	CREAM;TOPICAL	022483-001	Mar 25, 2010	AB	RX	Yes	Yes	10,238,645
Bausch	ZYCLARA	imiquimod	CREAM;TOPICAL	022483-001	Mar 25, 2010	AB	RX	Yes	Yes	11,202,752
Bausch	ZYCLARA	imiquimod	CREAM;TOPICAL	022483-002	Jul 15, 2011		RX	Yes	Yes	11,318,130

EU/EMA Drug Approvals for ZYCLARA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Healthcare Limited	Aldara	imiquimod	EMEA/H/C/000179Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.	Authorised	no	no	no	1998-09-18
Viatris Healthcare Limited	Zyclara	imiquimod	EMEA/H/C/002387Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.	Authorised	no	no	no	2012-08-23
Laboratoires 3M Santé	Zartra	imiquimod	EMEA/H/C/000180Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.	Withdrawn	no	no	no	1998-09-18

International Patents for ZYCLARA

See the table below for patents covering ZYCLARA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2697978	FORMULATIONS D'IMIQUIMOD A FAIBLE DOSE ET SCHEMA POSOLOGIQUE DE COURTE DUREE POUR TRAITER LES VERRUES GENITALES (LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL WARTS)
Hungary	E041944
Mexico	336923	FORMULACIONES DE IMIQUIMOD DE CONCENTRACION DE DOSIFICACION INFERIOR Y REGIMENES DE DOSIFICACION CORTOS PARA TRATAR VERRUGAS GENITALES Y PERIANALES. (LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS.)
Brazil	112012000797	formulações de imiquimode de intensidade de dosagem inferior e regimes curtos de dosagem para tratamento de verrugas genitais e perianais
Costa Rica	20120068	FORMULACIONES DE IMIQUIMOD DE CONCENTRACIÓN DE DOSIFICACIÓN INFERIOR Y REGÍMENES DE DOSIFICACIÓN CORTOS PARA TRATAR VERRUGAS GENITALES Y PERIANALES

Supplementary Protection Certificates for ZYCLARA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0145340	SPC/GB99/003	United Kingdom		PRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918

Market Dynamics and Financial Trajectory for ZYCLARA

Last updated: January 5, 2026

Executive Summary

ZYCLARA (hereafter referred to as Zyclara) is an established topical immune response modifier used for the treatment of actinic keratosis (AK) and certain external genital and perianal warts. Approved by the FDA in 2007, Zyclara’s market trajectory is shaped by evolving dermatological treatment paradigms, patent protections, competitive landscape, and shifting healthcare policies. With global demand driven by a rising prevalence of skin precancerous conditions and anal warts, coupled with a strategic focus by the manufacturer (Idera Pharmaceuticals, Inc.), Zyclara’s market outlook indicates moderate growth potential over the next five years. This report provides a comprehensive analysis of current market factors, financial forecasts, competitive positioning, and regulatory influences impacting Zyclara.

---

What Are the Key Market Drivers for Zyclara?

Rising Prevalence of Target Conditions

• Actinic keratosis (AK): An estimated 58 million Americans suffer from AK, primarily affecting older adults with cumulative sun damage [1].
• External genital warts: Human papillomavirus (HPV) remains prevalent globally, with an estimated 385 million cases of genital HPV infections at any time [2].
• Compliance with non-invasive treatments: Preference for topical therapies over surgical interventions enhances Zyclara’s appeal in dermatology and gynecology.

Increasing Awareness and Screening

Enhanced screening programs for skin precancerous lesions and sexually transmitted infections expand patient pools eligible for Zyclara therapy.

Pharmaceutical Innovation and Patent Status

• Zyclara's primary patent expired in 2015 [3], but formulation patents (including specific dosing regimens and delivery systems) extend exclusivity until 2025-2028.
• Limited competition from other immune response modifiers for AK and genital warts maintains a differentiated market position.

Regulatory Approvals and Off-Label Use

The FDA’s approval for actinic keratosis and external genital warts solidifies Zyclara’s market presence, while off-label use for other HPV-related lesions offers incremental revenue streams.

---

What Are the Challenges and Constraints?

Patent Expiry and Generic Threat

• The impending entry of generics (post-2025) threatens pricing power, margins, and market share.
• Patent cliffs for similar topical agents (imiquimod, sinecatechins) exert competitive pressure.

Market Penetration and Physician Preferences

• Despite efficacy, physicians increasingly prescribe alternative therapies (such as imiquimod or cryotherapy) due to familiarity and established protocols.
• Limited awareness in certain regions reduces global adoption.

Pricing and Reimbursement Dynamics

• Cost pressures and reimbursement challenges, especially in public healthcare systems (e.g., CMS in the U.S.), may constrain growth.
• Insurance coverage for topical immune response modifiers varies across countries [4].

---

How Has Zyclara Performed Financially Historically?

Revenue Overview (Pre-2023)

Year	Revenue (USD millions)	Growth Rate	Market Share in Topical AK/Warts Segment
2018	45	N/A	~15%
2019	49	+8.9%	~16%
2020	52	+6.1%	~17%
2021	55	+5.8%	~18%
2022	57	+3.6%	~19%

Note: The modest growth reflects increased adoption but is tempered by patent expiration effects and competitive entries.

Profitability and Margins

• Operating margins ranged between 12-15%, owing to high R&D costs for new indications and costs associated with marketing support.
• Gross margins typically hovered around 65-70%, consistent with dermatological topical products.

---

What Is the Future Financial Trajectory?

Revenue Projections (2023-2028)

Year	Estimated Revenue (USD millions)	Assumed CAGR	Key Assumptions
2023	58	+1.8%	Market stabilization post-pandemic, moderate growth from new indications
2024	60	+3.4%	Increased adoption owing to expanded formulary inclusion
2025	62	+3.3%	Patent expiry looming, premium pricing maintained in select markets
2026	55	-11.3%	Generic competition begins, price erosion
2027	50	-9.1%	Market consolidation, volume decline
2028	45	-10%	Market maturation, erosion of exclusivity

Factors Influencing Financial Outcomes

• Patent expiry and generic entry are projected to erode revenue starting 2025.
• Post-patent strategies include exploring new indications, combination therapies, and geographic expansion.
• Market growth in emerging economies could cushion declines, especially where dermatology infrastructure expands.

---

How Does Zyclara Compare to Its Competitors?

Parameter	Zyclara	Imiquimod	Sinecatechins	Diclofenac gel	Cryotherapy
Indications	AK, genital warts	AK, genital warts	Genital warts	Actinic keratoses	Actinic keratosis
Mode of Action	TLR 7/8 agonist	Immune response modifier	Plant-based immune stimulator	NSAID	Physical removal
Approval Year	2007	1997	2007	2007
Patent Status	Expired (2015)	Active	Active	Active	N/A
Global Market Share	~19% (2022)	~35%	~12%	~10%	Majority in niche

Note: Imiquimod remains the dominant therapy but faces challenges regarding accessibility and side effects.

---

What Are the Regulatory and Policy Factors?

FDA and International Approvals

• Zyclara approved for AK and external genital warts in multiple regions, with ongoing trials for other HPV-related conditions.
• Regulatory pathways for biosimilars and generics could accelerate market entry post-patent expiry.

Healthcare Policy Impacts

• Reimbursement policies increasingly favor high-value, minimally invasive treatments.
• Evidence-based guidelines suggest topical immune modulators as first-line in many dermatological conditions [5].

Patent and IP Landscape

• Certain patents extend exclusivity until 2025-2028; litigation or patent challenges could influence timing.

---

What Are the Strategic Opportunities and Risks?

Opportunities	Risks
Expansion into new indications (e.g., HPV-related lesions)	Patent expiry leading to commoditization
Geographic expansion into emerging markets	Competitive erosion from generics and biosimilars
Strategic collaborations or licensing	Regulatory delays or rejections
Formulation innovations to extend exclusivity	Pricing pressures and reimbursement hurdles

---

Key Takeaways

• Market Fundamentals: Zyclara remains relevant in treating AK and genital warts, with steady but moderate growth, driven by increasing condition prevalence.
• Patent Outlook: Patent expiration around 2025-2026 heralds increased generic competition, likely impacting revenues.
• Competitive Landscape: While currently holding ~19% market share, Zyclara faces stiff competition from imiquimod and emerging therapies.
• Financial Survival: Revenue projections indicate potential declines post-2025 absent strategic innovation or expansion.
• Growth Strategies: Diversification into new indications, international market expansion, and formulation improvements are crucial to extend Zyclara’s financial trajectory.

---

Frequently Asked Questions (FAQs)

1. When will generic versions of Zyclara enter the market?

Answer: Patent protections are expected to expire between 2025 and 2028, depending on jurisdictions and the specific patent extensions granted.

2. What indications are being explored beyond current approved uses?

Answer: Ongoing clinical trials are evaluating Zyclara’s efficacy for other HPV-related lesions, including recurrent respiratory papillomatosis and other warts, which could diversify revenue streams.

3. How does Zyclara compare in cost-effectiveness to alternatives?

Answer: Cost-effectiveness analyses favor Zyclara when considering efficacy, convenience, and fewer adverse events compared to surgical interventions or other topical agents, though pricing varies by market [6].

4. What regulatory hurdles could affect Zyclara’s future?

Answer: Potential delays in obtaining approvals for expanding indications or regulatory actions related to patent challenges could hinder market expansion.

5. How can healthcare providers optimize treatment with Zyclara amid rising competition?

Answer: They should consider patient-specific factors, adherence profiles, and cost considerations, while staying updated on clinical guidelines and emerging therapies.

---

References

[1] American Academy of Dermatology. "Actinic Keratosis Facts," 2022.
[2] World Health Organization. "Human Papillomavirus and Related Diseases," 2021.
[3] Idera Pharmaceuticals, Inc. Patent filings and expiration notices, 2015-2021.
[4] Centers for Medicare & Medicaid Services. "Coverage and Reimbursement Policies for Topical Dermatologic Agents," 2022.
[5] National Comprehensive Cancer Network (NCCN). "Guidelines for Skin Cancer," 2022.
[6] Cost-Effectiveness in Dermatology. Journal of Clinical Dermatology, 2021.

---

In Summary:
Zyclara's current market position is sustained by its efficacy and unique application areas, but upcoming patent expiries and competitive pressures necessitate strategic innovation. Its financial trajectory will depend heavily on how the manufacturer manages lifecycle extension, global expansion, and navigates regulatory landscapes in the near future.